Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hellebø replaces Hunt at the helm of stem cell firm ReNeuron

This article was originally published in Clinica

Executive Summary

UK stem cell specialist ReNeuron has appointed pharma veteran Olav Hellebø CEO with immediate effect. Mr Hellebø has experience at both large pharma firms and small biotechs, having most recently headed up Norway’s Clavis Pharma, where he took the company’s lead program through Phase III clinical development as well as completing “substantial” fundraising and out-licensing transactions. Before this, he was in charge of the global biologics franchise at UCB Pharma, and was previously head of UK commercial operations of Novartis. He has also worked for Schering-Plough, where he held a number of senior commercial roles in Europe and the US. Mr Hellebø replaces long-time ReNeuron chief Michael Hunt, who in April announced his intention to become the firm’s CFO after leading the company since July 2005. ReNeuron’s most advanced product is ReN001 for the treatment of the effects of stroke, which is currently in a Phase II trial with results expected at the end of 2015, according to the firm’s website.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101899

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel